



ABIVAX abstract on ABX464 selected for presentation at the AIDS 2016 Conference in Durban, South Africa

April 27, 2016

Details

Published on Wednesday, 27 April 2016 18:00

Paris, April 27th, 2016 - ABIVAX (Euronext Paris: FR0012333284 – ABVX), an emerging leader in developing and commercializing anti-viral therapies and therapeutic vaccines for infectious diseases like HIV/AIDS and chronic hepatitis B (CHB), today announced that its abstract entitled, ***“Antiviral activity and safety of ABX464 in HIV-infected treatment-naïve patients”*** has been selected for presentation at the 21st International AIDS Conference (AIDS 2016) to be held in Durban, South Africa, 18-22 July 2016. The date and time of the presentation will be communicated in the coming weeks.